Company merger new corporate identity
Isorg
INNOVATION: MARKET AWARENESS + POSITION MESSAGING
Clean cells
Investment: New production site
Carthera
DIGITAL COMMUNICATIONS: TWITTER
Aglaia Therapeutics becomes Ribonexus and signs exclusive license agreement with Pierre Fabre on small molecules targeting
Lynred boosts thermal sensitiviity across range of 12-micron infrared detectors
Genoskin appoints DR Nicolas Gaudenzio as chief scientific officer
World-renowned expert in immunology and allergic skin inflammation, Dr Nicolas Gaudenzio has just been appointed as CSO of ex vivo clinical testing specialist Genoskin. He also leads a research group at Inserm – the French National Institute of Health and Medical Research – in the field of skin neuro-immunology, inflammation and imaging
His expertise in skin immunology and imaging of the human immune system will guide Genoskin’s strategic shift towards immunology expert services for the pharmaceutical industry
PDC*line Pharma opens last cohort of PDC-LUNG-101 clinical trial
B2 cohort (high dose added to anti-PD-1) of the PDC-LUNG-101 trial with PDC*lung01 therapeutic cancer vaccine candidate for non-small cell lung cancer has been opened and first patients were dosed
Biomunex Pharmaceutical’s breakthrough immunotherapy project receives grants close to €3 Million
Led by Biomunex alongside Institut Curie and GTP Bioways, with a total budget of €5.6 million, BiXAb5 non-conventional T cell redirection project seeks to create breakthrough immunotherapy approach to cancer treatment based on bispecific antibodies
Minafin’s health chemistry division launches Blendamix, custom powder premix manufacturing service for food and pharma applications
Blendamix offers both raw material sourcing and 750 ton/year manufacturing capacity of very homogenous on-demand blends in any type of powdered ingredient
Blendamix will debut at CPhl Worldwide in Milan, Italy, November 9 – 11, 2021, at stand #5D21